NCT05756166 2025-06-24
Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer
Roswell Park Cancer Institute
Phase 1/2 Terminated
Clinical Trials
21 trialsNCT02432378 2025-06-19
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
Roswell Park Cancer Institute
Phase 1/2 Terminated
NCT01545141 2023-10-27
Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer
Roswell Park Cancer Institute
Phase 1/2 Terminated
NCT02054104 2022-01-26
Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT02770378 2021-10-05
A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma
University of Ulm
Phase 1/2 Completed
NCT02151448 2020-07-20
αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies
University of Pittsburgh
Phase 1/2 Completed
NCT01425476 2017-08-09
Changes in Breast Cancer Biomarkers Using Synergistic Prostaglandin Inhibitors
Hartford Hospital
Phase 1/2 Completed
NCT01769625 2017-08-09
Changes in Biomarkers Using Prostaglandin Inhibitors
Hartford Hospital
Phase 1/2 Completed
NCT00159484 2017-06-27
Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer
University of Southern California
Phase 1/2 Unknown
NCT00970502 2017-04-10
Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer
Icahn School of Medicine at Mount Sinai
Phase 1/2 Completed
NCT00152828 2016-02-09
Celebrex - Cervix: Celecoxib in the Treatment of Patients With Locally Advanced Carcinoma of the Cervix
University Health Network, Toronto
Phase 1/2 Completed
NCT01021215 2015-04-02
Zileuton With or Without Celecoxib As Chemopreventive Agents in Smokers
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00314262 2014-10-24
Phase I/II Study of Chemoprevention With EGFR and COX-2 Inhibitor
Emory University
Phase 1/2 Completed
NCT00023660 2013-11-19
Radiation Therapy Plus Celecoxib, Fluorouracil, and Cisplatin in Patients With Locally Advanced Cervical Cancer
Radiation Therapy Oncology Group
Phase 1/2 Completed
NCT00581971 2013-04-25
RAD0201
University of Alabama at Birmingham
Phase 1/2 Completed
NCT00293436 2012-09-17
Celecoxib and Erlotinib in Treating Patients With Liver Cancer
University of California, San Francisco
Phase 1/2 Withdrawn
NCT00073866 2012-07-19
Combination Chemotherapy and Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer
Northwestern University
Phase 1/2 Completed
NCT00212108 2012-04-02
A Study Of Nasopharyngeal Carcinoma (NPC) Treated With Celecoxib And ZD1839
National University Hospital, Singapore
Phase 1/2 Completed
NCT00357617 2010-12-24
Celecoxib in Treating Patients With Head and Neck Cancer That Can Be Removed By Surgery
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT00188565 2010-08-13
Celebrex With Preoperative Chemoradiation - Rectal Cancer
University Health Network, Toronto
Phase 1/2 Completed
NCT00197912 2010-04-26
Dendritic Cell Based Therapy of Malignant Melanoma
Herlev Hospital
Phase 1/2 Completed